SEC Form 4 · accession 0001209191-16-130106
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 27, 2016
Accepted (ET)
Jun 29, 2016 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 27, 2016 | P | 76,923 | $13.00 | A | 1,187,365 | D | |
| Common StockF1,F3 | Jun 27, 2016 | P | 384,615 | $13.00 | A | 779,802 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Persons are part of a "group" as defined in Rule 13d-5 promulgated under the Securities Exchange Act of 1934, as amended (which group also includes K/S Danish BioVenture ("Danish BV") and Danish BioVenture General Partner ApS, whose securities are beneficially owned by Clessidra, LLC. This group beneficially owns, in the aggregate, 2,600,410 shares of common stock of the issuer and warrants to purchase an additional 6,412 shares of common stock of the issuer.
- F2The reported securities are held in the name of Omega Fund III, L.P. ("Omega III"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein.
- F3The reported securities are held in the name of Omega Fund IV, L.P. ("Omega IV"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein.